Shopping Cart
- Remove All
Your shopping cart is currently empty
CEP57 Protein, Human, Recombinant (GST)
Catalog No. TMPY-04025
CEP57 is a centrosomal protein and is involved in nucleating and stabilizing microtubules. CEP57 was initially identified as a regulator of centriole overduplication in an RNA interference screen. There is a link between altered microenvironmental signaling cues such as FGF-2 overexpression and mitotic instability and provide a rationale for the therapeutic targeting of the FGF-2/FGFR1/CEP57 axis in prostate cancer. CEP57 is involved in intracellular transport processes, and its overexpression causes mitotic defects as well as abnormal microtubule nucleation and bundling.
CEP57 Protein, Human, Recombinant (GST)
Catalog No. TMPY-04025
CEP57 is a centrosomal protein and is involved in nucleating and stabilizing microtubules. CEP57 was initially identified as a regulator of centriole overduplication in an RNA interference screen. There is a link between altered microenvironmental signaling cues such as FGF-2 overexpression and mitotic instability and provide a rationale for the therapeutic targeting of the FGF-2/FGFR1/CEP57 axis in prostate cancer. CEP57 is involved in intracellular transport processes, and its overexpression causes mitotic defects as well as abnormal microtubule nucleation and bundling.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 μg | $700 | 7-10 days |
Bulk & Custom
Add to Cart
Resource Download
Product Information
| Biological Activity | Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
| Description | CEP57 is a centrosomal protein and is involved in nucleating and stabilizing microtubules. CEP57 was initially identified as a regulator of centriole overduplication in an RNA interference screen. There is a link between altered microenvironmental signaling cues such as FGF-2 overexpression and mitotic instability and provide a rationale for the therapeutic targeting of the FGF-2/FGFR1/CEP57 axis in prostate cancer. CEP57 is involved in intracellular transport processes, and its overexpression causes mitotic defects as well as abnormal microtubule nucleation and bundling. |
| Species | Human |
| Expression System | E. coli |
| Tag | N-GST |
| Accession Number | Q86XR8-1 |
| Synonyms | TSP57,PIG8,MVA2,centrosomal protein 57kDa |
| Construction | A DNA sequence encoding the human CEP57 (Q86XR8-1) (Ser118-Arg226) was expressed with the GST tag at the N-terminus. Predicted N terminal: Met |
| Protein Purity | > 90 % as determined by SDS-PAGE |
| Molecular Weight | 40.3 kDa (predicted); 35-43 kDa (reducing conditions) |
| Endotoxin | Please contact us for more information. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
| Reconstitution | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
| Stability & Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, Lyophilized powders are shipping with blue ice. |
| Research Background | CEP57 is a centrosomal protein and is involved in nucleating and stabilizing microtubules. CEP57 was initially identified as a regulator of centriole overduplication in an RNA interference screen. There is a link between altered microenvironmental signaling cues such as FGF-2 overexpression and mitotic instability and provide a rationale for the therapeutic targeting of the FGF-2/FGFR1/CEP57 axis in prostate cancer. CEP57 is involved in intracellular transport processes, and its overexpression causes mitotic defects as well as abnormal microtubule nucleation and bundling. |
Dose Conversion
You can also refer to dose conversion for different animals. More
Calculator
Tech Support
Please read the User Guide of Recombinant Proteins for more specific information.
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.